Celularity Regains Compliance with Nasdaq Periodic Reporting RequirementGlobeNewsWire · 2 days ago
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic PartnerGlobeNewsWire · Sep 30, 2026
Celularity Announces Naveen Jain to Join Board of DirectorsGlobeNewsWire · Sep 29, 2026
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating ImprovementsGlobeNewsWire · Sep 24, 2026
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® PlatformGuruFocus · Aug 27, 2026
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® PlatformBusiness Wire · Aug 27, 2026Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking.